Austral Capital
VC Fund
Santiago, Chile
Austral Capital is a venture capital firm that invests in leading technology services companies located in Chile, Colombia, Peru and Mexico that have the potential to accelerate their growth through expanded service and solution offerings in the region. The firm mainly invests in growth-stage companies that provide core digital platforms for thefinancial, retail and healthcare markets.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Austral Capital invests in
SoftwareElectronicsEnterprise SoftwareInformation TechnologyFuel
Stages Austral Capital invests in
Funding RoundSeedSeries ASeries B
Countries Austral Capital invests in
United StatesChile
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Investment Focus
Industry
- Software 2 (20%)
- Electronics 2 (20%)
- Enterprise Software 2 (20%)
- Information Technology 2 (20%)
- Fuel 1 (10%)
Stage
- Funding Round 3 (30%)
- Seed 2 (20%)
- Series A 2 (20%)
- Series B 1 (10%)
Country
- United States 4 (40%)
- Chile 3 (30%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Gonzalo Miranda
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
Hiroshi Wald
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
| CFO | Total investments: 0 | Find email | ||
Nicolas Zarges
Principal
|
Principal | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Andes Biotechnologies
|
Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers. The Company has discovered two novel families of long non-coding RNAs: sense (S-RNA) and antisense (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus.Theproprietary technology developed by Andes Biotechnologies is based on oligonucleotide drugs that target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis.Andes Biotechnologies has an active investigational new drug (IND) application in the United States and is currently engaged in the clinical development of its lead drug Andes-1537.Andes Biotechnologies is supported by a proven and experienced management team, a robust network of key national and international collaborators in the cancer field, and has an extensive intellectual property portfolio.Andes Biotechnologies was founded in 2008 and is located in Santiago, Chile. | Dec 23, 2014 | |
Scopix
|
SCOPIX is the market leader in intelligent video analytics for retailers, CPG companies and manufactures. Our Real.Suite ™ family of cloud based solutions collects data and returns timely, actionable information via a web based portal to store personnel, regional managers and corporate executives to help them maximize the customer experiencethroughout the entire store. SCOPIX solutions are proven to enhance retail business operations, drive sales and maximize profits. | $4.8M / Jul 02, 2012 | |
Junar
|
Junar powers the Data Economy by delivering the easiest-to-use, cloud-based Open Data platform. For innovative organizations, Junar is the fastest way to publish data. The Junar platform enables businesses, governments, and organizations to free their data to drive new opportunities, collaboration, and transparency. Some of the world'sleading companies trust Junar with their most valuable assets: their data and the end users who are viewing and using it. | $1.2M / Seed / May 29, 2012 | |
Nimbic
|
Nimbic is a provider of SaaS-based, cloud computing electronic design automation (EDA) solutions. Nimbic enables high-speed and high-capacity 3D electromagnetic signal integrity, power integrity and EMI analysis field solutions for the microelectronics industry. Nimbic's global customers include Texas Instruments, Renesas, Toshiba, Tabula andPanasonic. Nimbic's nCloud solution facilitates efficient and robust chip-package-system co-design while significantly reducing time-to-market and costs. Nimbic's accelerated technology delivers unprecedented capacity handling, significantly faster speed than current methodologies, and the ability to span the entire design cycle in 3D IC, package and system simulations, while maintaining uncompromising Maxwell accuracy. | $444K / Jan 01, 2012 | |
|
Nimbic
|
Nimbic is a provider of SaaS-based, cloud computing electronic design automation (EDA) solutions. Nimbic enables high-speed and high-capacity 3D electromagnetic signal integrity, power integrity and EMI analysis field solutions for the microelectronics industry. Nimbic's global customers include Texas Instruments, Renesas, Toshiba, Tabula andPanasonic. Nimbic's nCloud solution facilitates efficient and robust chip-package-system co-design while significantly reducing time-to-market and costs. Nimbic's accelerated technology delivers unprecedented capacity handling, significantly faster speed than current methodologies, and the ability to span the entire design cycle in 3D IC, package and system simulations, while maintaining uncompromising Maxwell accuracy. | $6.9M / Series B / Jun 02, 2011 | |
|
Andes Biotechnologies
|
Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers. The Company has discovered two novel families of long non-coding RNAs: sense (S-RNA) and antisense (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus.Theproprietary technology developed by Andes Biotechnologies is based on oligonucleotide drugs that target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis.Andes Biotechnologies has an active investigational new drug (IND) application in the United States and is currently engaged in the clinical development of its lead drug Andes-1537.Andes Biotechnologies is supported by a proven and experienced management team, a robust network of key national and international collaborators in the cancer field, and has an extensive intellectual property portfolio.Andes Biotechnologies was founded in 2008 and is located in Santiago, Chile. | May 19, 2011 | |
Bio Architecture Lab
|
Bio Architecture Lab is a pioneer in the application of synthetic biology and enzyme design to the development of biofuels and renewable chemicals from aquafarmed, native macroalgae (seaweed), which is a low cost, scalable, and sustainable biomass. | $8M / Series A / Nov 23, 2009 | |
Atakama Labs
|
Atakama Labs is a developer, publisher and operator of social games, focused on meaningful games. They are making games that will make the world a better place, while entertaining and surprising their players. Their games tend to be free to play so that everyone can enjoy them. They develop primarily in Chile and publish their products across theglobe, both directly and together with partners, depending on the platform and territory. Atakama is backed by Austral Capital and the COPEC-UC Fund, two venture capital funds. | Seed / Aug 01, 2009 | |
Paperless
|
Paperless is an electronic receipts and electronic document management company in Latin America, processing over two billion documents per year for global enterprise businesses. | Series A / Apr 10, 2008 | |
|
Andes Biotechnologies
|
Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers. The Company has discovered two novel families of long non-coding RNAs: sense (S-RNA) and antisense (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus.Theproprietary technology developed by Andes Biotechnologies is based on oligonucleotide drugs that target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis.Andes Biotechnologies has an active investigational new drug (IND) application in the United States and is currently engaged in the clinical development of its lead drug Andes-1537.Andes Biotechnologies is supported by a proven and experienced management team, a robust network of key national and international collaborators in the cancer field, and has an extensive intellectual property portfolio.Andes Biotechnologies was founded in 2008 and is located in Santiago, Chile. | Series B |
Co-Investors
Aurus
2 deals together
Band of Angels
1 deal together
Fondo de Inversión Privado Copec-UC
1 deal together
Energy Capital Management
1 deal together
Washington Research Foundation
1 deal together
XSeed Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
99,274 investors
Enterprise Investors
77,348 investors
Software Investors
50,021 investors
Hardware Investors
40,144 investors
Consumer Investors
32,380 investors
Energy Investors
25,111 investors
Enterprise Software Investors
13,836 investors
SaaS VC Funds
61,208 investors
Enterprise VC Funds
49,693 investors
FAQ
What does Austral Capital invest in?
Austral Capital invests primarily in Software, Electronics and Enterprise Software startups, most often at Funding Round and Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Austral Capital?
Public channels for Austral Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Austral Capital?
The team at Austral Capital includes Gonzalo Miranda (Founding Partner), Hiroshi Wald (Managing Director) and Mauricio Espinoza Navarrete (CFO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
